Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Reducing the timeline from conception to Phase 1 trials can be especially challenging for new and emerging biotechs. Since many of them are completely virtual or have limited lab space capabilities, they often do not have in-house resources and capacity for formulation development. Without the ability to move smoothly from lab concept to the manufacture and delivery of GMP clinical supplies to patients, critical milestones could be missed, potentially delaying funding commitments from investors.
Download this white paper to learn more about:
- Securing the future of your molecule
- Strategies to lay the foundation for commercial success
- Case studies